Needham Downgrades Verrica Pharmaceuticals to Hold, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has downgraded Verrica Pharmaceuticals from Buy to Hold, while maintaining a $12 price target.
October 03, 2024 | 9:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Serge Belanger downgraded Verrica Pharmaceuticals from Buy to Hold, maintaining a $12 price target. This suggests a neutral outlook on the stock's short-term performance.
The downgrade from Buy to Hold indicates a shift in the analyst's perspective, suggesting that the stock may not outperform in the short term. However, the maintained price target of $12 implies that the analyst still sees value at the current price level, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100